Arnold M. Baskies
Known title: DirectorCIK: 0001683567
Arnold M. Baskies's purchase track record
How the stock did after each of Arnold M. Baskies's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 6 since March 15, 2024
Stock higher 6 months later
40%
3 months: 40%
Median 6-month return
-7.3%
3 months: -1.8%
Beat the S&P 500
40%
median -17.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/24/2026 | ANIX | $14K | pending | pending | — |
| 1/28/2026 | ANIX | $30K | -5.0% | +14.8% | +4.9% |
| 7/18/2025 | ANIX | $17K | +19.2% | -7.3% | +10.2% |
| 1/28/2025 | ANIX | $14K | -1.8% | +10.7% | +5.0% |
| 7/26/2024 | ANIX | $15K | +6.6% | -7.5% | +11.8% |
| 3/15/2024 | ANIX | $36K | -29.3% | -9.2% | +10.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANIX | ▲ Buy | Open Market | 5,000 | $14K | 9/24/2026 | View on chart |
| ANIX | ▲ Buy | Option Exercise | 6,000 | $19K | 7/27/2026 | View on chart |
| ANIX | ▼ Sell | Tax Withholding | 5,428 | $19K | 7/27/2026 | View on chart |
| ANIX | ▲ Buy | Open Market | 10,000 | $30K | 1/28/2026 | View on chart |
| ANIX | ▲ Buy | Open Market | 5,000 | $17K | 7/18/2025 | View on chart |
| ANIX | ▲ Buy | Open Market | 5,000 | $14K | 1/28/2025 | View on chart |
| ANIX | ▲ Buy | Open Market | 5,000 | $15K | 7/26/2024 | View on chart |
| ANIX | ▲ Buy | Open Market | 10,000 | $36K | 3/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Anixa Biosciences Secures First Australian Patent for Breast Cancer Vaccine
Anixa Biosciences received its first Australian patent for its breast cancer vaccine technology, extending global protection through 2040. This milestone strengthens the company's intellectual property position for a product exclusively licensed from the Cleveland Clinic. While HC Wainwright & Co. recently lowered its price target to $6, the patent grant provides a concrete regulatory and legal development for the stock.
Anixa Biosciences Secures First Australian Patent for Breast Cancer Vaccine. Anixa Biosciences received its first Australian patent for its breast cancer vaccine technology, extending global protection through 2040. This milestone strengthens the company's intellectual property position for a product exclusively licensed from the Cleveland Clinic. While HC Wainwright & Co. recently lowered its price target to $6, the patent grant provides a concrete regulatory and legal development for the stock.